Qulipta (atogepant) is a once-daily oral CGRP receptor antagonist approved for preventing episodic migraine (fewer than 15 headache days/month) and chronic migraine (15+ headache days/month). It comes in three doses: 10mg, 30mg, and 60mg daily, with the higher doses used for chronic migraine. Unlike injectable CGRP antibodies (Aimovig, Ajovy, Emgality), it is a pill taken daily — the first oral CGRP-targeting preventive that is exclusively preventive (not used for acute attacks). Most patients see meaningful reduction in migraine days within the first 4 weeks.
For people who want a CGRP-targeted preventive without injections, and who don't need Nurtec's dual acute/preventive action, Qulipta fills a distinct niche: dedicated daily oral prevention.
Medical Quick Facts
| Fact | Answer |
|---|---|
| Drug class | CGRP receptor antagonist (gepant) |
| Brand name | Qulipta |
| Doses | 10mg (episodic), 30mg, 60mg (chronic migraine) |
| Frequency | Once daily |
| Approved for | Episodic migraine prevention; chronic migraine prevention |
| Onset of effect | Reduction in migraine days seen within 4 weeks |
| Full effect | 8–12 weeks |
| Form | Oral tablet |
Qulipta vs. Injectable CGRP Preventives
The injectable CGRP antibodies — Aimovig (erenumab), Ajovy (fremanezumab), Emgality (galcanezumab), Vyepti (eptinezumab IV) — target either the CGRP peptide or its receptor. Qulipta also targets the receptor (same target as Aimovig), but as a small-molecule pill rather than a large-molecule antibody.
| | Qulipta (Atogepant) | Injectable CGRP Antibodies |
|---|---|---|
| Form | Daily oral pill | Monthly or quarterly injection (or IV infusion) |
| Onset | 4 weeks | 4–8 weeks |
| Half-life | ~11 hours (leaves body quickly) | Weeks to months |
| Side effects wear off | Within days of stopping | Slowly over weeks/months |
| Drug interactions | CYP3A4 pathway | Few |
| Self-administered | Yes (oral) | Yes (auto-injector) or clinic (IV) |
For someone who tried an injectable CGRP antibody and did not tolerate side effects, switching to Qulipta (different form factor, shorter half-life) may produce a different side-effect profile.
How Well Does It Work?
In the ADVANCE trial (episodic migraine), patients on Qulipta 60mg experienced approximately 4 fewer migraine days per month vs placebo at 12 weeks. In the PROGRESS trial (chronic migraine), 60mg patients had about 7 fewer headache days per month.
Approximately 40–60% of patients achieve a 50% or greater reduction in monthly migraine days, which is the standard benchmark for a "responder" to preventive therapy.
Common Side Effects
- Constipation — the most frequently reported side effect (6–12% depending on dose); increase fiber and hydration
- Nausea — usually mild and temporary
- Fatigue
Qulipta does not cause the cognitive side effects ("brain fog") associated with topiramate, and does not affect weight. There are no mood-related effects like those sometimes seen with antidepressant-class preventives.
Drug Interactions
Qulipta is metabolized by CYP3A4 and is also a substrate of OATP and P-glycoprotein transporters:
- Strong CYP3A4 inhibitors: Reduce Qulipta dose to 10mg daily
- Strong CYP3A4 inducers: Avoid co-administration (greatly reduces effectiveness)
- OATP inhibitors (e.g., cyclosporine): Avoid or reduce dose
Frequently Asked Questions
How is Qulipta different from Nurtec for prevention?
Both are gepants. Nurtec is taken every other day and also treats acute attacks on the same tablet. Qulipta is taken daily (not acute), comes in three dose strengths, and is specifically approved for both episodic and chronic migraine prevention. Qulipta offers more dose flexibility for higher-frequency migraine.
Can I take a triptan for attacks while on Qulipta?
Yes. Qulipta is a preventive; you should still use an acute treatment (triptan, gepant, NSAID) for breakthrough attacks. Having both is the standard approach.
What if Qulipta doesn't work?
Give it at least 8–12 weeks at the target dose before evaluating response. If there is no meaningful reduction in migraine days, an injectable CGRP antibody (different mechanism/half-life), or an older preventive (amitriptyline, topiramate, propranolol), may be a better fit.
Track monthly migraine days carefully in Migraine Trail before starting and for the first 3 months of Qulipta — this baseline and treatment data is what lets you and your neurologist make an evidence-based decision about whether to continue, adjust, or change strategy.
